Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial.

Author(s): Vesikari T, Karvonen A, Bianco V, Van der Wielen M, Miller J

Affiliation(s): Vaccine Research Center, University of Tampere Medical School, Tampere, Finland. timo.vesikari@uta.fi

Publication date & source: 2011-06-06, Vaccine., 29(25):4274-84. Epub 2011 Apr 6.

Publication type: Comparative Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Co-administration of meningococcal ACWY-tetanus toxoid conjugate vaccine (ACWY-TT) with MMRV vaccine was investigated in 1000 12-23-month old children randomized (3:3:1:1) to receive co-administered ACWY-TT+MMRV, or a single dose of ACWY-TT, MMRV or MenC-CRM(197). Non-inferiority of ACWY-TT to MenC-CRM(197) and non-inferiority of ACWY-TT+MMRV to ACWY-TT and MMRV alone, and the immunogenicity of serogroups AWY were demonstrated according to pre-defined criteria. Fever reactions in ACWY+MMRV and MMRV groups were comparable. ACWY-TT can be co-administered with MMRV without affecting immunogenicity or safety profiles of either vaccine. This study has been registered at www.clinicaltrials.gov NCT00474266. Copyright (c) 2011 Elsevier Ltd. All rights reserved.